|Bid||13.20 x 900|
|Ask||13.39 x 1000|
|Day's Range||12.82 - 13.54|
|52 Week Range||9.59 - 50.20|
|Beta (5Y Monthly)||2.04|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.00|
Subscribe to Yahoo Finance Plus to view Fair Value for EDIT
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders should be happy to see the share price up 27% in the last quarter...
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: 2022 Wells Fargo Healthcare Conference Format: Fireside ChatDate: Wednesday, September 7, 2022Time: 1:55 p.m. ETLocation: Everett, MA Morgan Stanley 20th Annual Global Healthcare Conference Format: Fireside ChatDate: Monday, September 12, 2022Time: 10:30 a.m. ETLocation: New Yo